Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.
(2013) In Journal of Clinical Oncology 31(35). p.4453-4461- Abstract
- Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4179523
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- 31
- issue
- 35
- pages
- 4453 - 4461
- publisher
- American Society of Clinical Oncology
- external identifiers
-
- wos:000328817400012
- pmid:24220555
- scopus:84894297251
- pmid:24220555
- ISSN
- 1527-7755
- DOI
- 10.1200/JCO.2013.51.0826
- language
- English
- LU publication?
- yes
- id
- 9d49128d-481e-4770-b190-4102eca35e30 (old id 4179523)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24220555?dopt=Abstract
- date added to LUP
- 2016-04-01 10:03:13
- date last changed
- 2022-02-24 21:54:01
@article{9d49128d-481e-4770-b190-4102eca35e30, abstract = {{Gemcitabine requires transporter proteins to cross cell membranes. Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. We conducted a randomized controlled trial to determine whether CO-101 improved survival versus gemcitabine in patients with metastatic PDAC (mPDAC) with low hENT1. The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression.}}, author = {{Poplin, Elizabeth and Wasan, Harpreet and Rolfe, Lindsey and Raponi, Mitch and Ikdahl, Tone and Bondarenko, Ihor and Davidenko, Irina and Bondar, Volodymyr and Garin, August and Boeck, Stefan and Ormanns, Steffen and Heinemann, Volker and Bassi, Claudio and Evans, T R Jeffrey and Andersson, Roland and Hahn, Hejin and Picozzi, Vince and Dicker, Adam and Mann, Elaina and Voong, Cynthia and Kaur, Paramjit and Isaacson, Jeff and Allen, Andrew}}, issn = {{1527-7755}}, language = {{eng}}, number = {{35}}, pages = {{4453--4461}}, publisher = {{American Society of Clinical Oncology}}, series = {{Journal of Clinical Oncology}}, title = {{Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity.}}, url = {{http://dx.doi.org/10.1200/JCO.2013.51.0826}}, doi = {{10.1200/JCO.2013.51.0826}}, volume = {{31}}, year = {{2013}}, }